Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis.

teriflunomide - Generic mfg.

Ponvory (ponesimod) - Juvise Pharma, Vanda

Mavenclad (cladribine) - EMD Serono

Ocrevus (ocrelizumab) - Roche

Kesimpta (ofatumumab subcutaneous) - Novartis, Genmab

glatiramer acetate - Generic mfg.

Lemtrada (alemtuzumab) - Sanofi

Tysabri (natalizumab) - Biogen, Royalty

dimethyl fumarate - Generic mfg.

Zeposia (ozanimod) - BMS

fingolimod - Generic mfg.

siponimod - Generic mfg.

Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis. (PubMed, Neurol Res Pract) - Oct 23, 2026 - "These associations are candidates for which specific effects of Natalizumab and Fingolimod should be identified that increase vulnerability to respective infections."
Journal • CNS Disorders • Herpes Zoster • Infectious Disease • Multiple Sclerosis • Pneumococcal Infections • Rare Diseases • Varicella Zoster

http://www.ncbi.nlm.nih.gov/pubmed/42907929

Frederike Kadgien; Katja Hummel; Peter Trillenberg

Oct 23, 2026